Retrograde coronary perfusion: A superior route to deliver therapeutics to the heart?

Journal of the American College of Cardiology

Volumn 42, Issue 6, 2003, Pages 1129-1131

  Giordano, Frank J ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; UNCLASSIFIED DRUG;

ADENOVIRUS; ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL RUPTURE; CANNULATION; CORONARY ARTERY BLOOD FLOW; CORONARY SINUS; DRUG DELIVERY SYSTEM; HEART MUSCLE ISCHEMIA; INTRACORONARY INFUSION; NONHUMAN; NOTE; PRIORITY JOURNAL; SWINE; TECHNIQUE;

EID: 0043236414     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00903-3     Document Type: Editorial

References (25)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
2. von Degenfeld G, Raake P, Kupatt C, et al. Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia. J Am Coll Cardiol 2003;42:1120-8.
3. Post MJ, Laham R, Sellke FW, Simons M. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 2001;49:522-31.
4. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2534-9.
5. Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor-2 protein. J Thorac Cardiovasc Surg 2002;124:28-34.
6. Schumacher B, Pecher P, von Specht B U, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-50.
7. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-4.
8. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-74.
9. Lazarous DF, Shou M, Stiber JA, et al. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res 1999;44:294-302.
10. Kornowski R, Leon MB, Fuchs S, et al. Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models. J Am Coll Cardiol 2000;35:1031-9.
11. Isner JM. Myocardial gene therapy. Nature 2002;415:234-9.
12. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000;102:E73-86.
13. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
14. Henry TD, Annex BH, McKendall GR, et al., the VIVA Investigators. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-65.
15. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
16. GenVec Inc. Available at: www.genvec.com. Accessed March 2003.
17. Rebar EJ, Huang Y, Hickey R, et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med 2002;8:1427-32.
18. Laham RJ, Rezaee M, Post M, et al. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos 1999;27:821-6.
19. Ikeda Y, Gu Y, Iwanaga Y, et al. Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation 2002;105:502-8.
20. Beeri R, Guerrero JL, Supple G, Sullivan S, Levine RA, Hajjar RJ. New efficient catheter-based system for myocardial gene delivery. Circulation 2002;106:1756-9.
21. Miyazaki A, Tadokoro H, Drury JK, Ryden L, Haendchen RV, Corday E. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis. J Am Coll Cardiol 1991;18:613-20.
22. Lee R, Nitta T, Schmid RA, Schuessler RB, Harris KM, Gay WA Jr. Retrograde infusion of lidocaine or L-arginine before reperfusion reduces myocardial infarct size. Ann Thorac Surg 1998;65:1353-9.
23. Hou D, Maclaughlin F, Thiesse M, et al. Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery. Catheter Cardiovasc Interv 2003;58:207-11.
24. Li J, Post M, Volk R, et al. PR39, a peptide regulator of angiogenesis. Nat Med 2000;6:49-55.
25. Kurusz M, Girouard MK, Brown PS Jr. Coronary sinus rupture with retrograde cardioplegia. Perfusion 2002;17:77-80.